Avicanna (TSX:AVCN) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Avicanna ROE % Adjusted to Book Value?

Avicanna's ROE % for the quarter that ended in Dec. 2023 was -2,676.32%. Avicanna's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Avicanna's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.

Avicanna ROE % Adjusted to Book Value Historical Data

The historical data trend for Avicanna's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna ROE % Adjusted to Book Value Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-42.98

-29.67

-15.01

Avicanna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-84.77	-28.62	-12.44	-

Competitive Comparison of Avicanna's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avicanna's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avicanna's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Avicanna's ROE % Adjusted to Book Value falls into.

Avicanna ROE % Adjusted to Book Value Calculation

Avicanna's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Avicanna's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-2,676.32%	/	N/A
	=	N/A

Avicanna ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Avicanna's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Avicanna (TSX:AVCN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

AVCNF:USA 0NN:Germany

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

Executives

Sheldon Inwentash

10% Security Holder

Avicanna (TSX:AVCN) Headlines

No Headlines